Prognostic factors in COPP-treated patients with Hodgkin's disease
- PMID: 7082859
- DOI: 10.1007/BF00319917
Prognostic factors in COPP-treated patients with Hodgkin's disease
Abstract
In a recently published review of the literature [40] we came to the conclusion that the Ann-Arbor staging classification is of limited prognostic value for chemotherapy of Hodgkin's disease (Table 2). Four risk factors accounted for impaired complete remission rates: stage IVB, lymphocyte depletion or not classifiable histologic type, previous chemotherapy, and older age. Fifty-eight evaluable patients were treated with COPP; 23 reached a complete remission (40%). Disease-free survival was 31%, overall survival 49% after five years [33]. Besides the known risk factors, impaired bone marrow function (leucocyte counts less than 4 X 10(9)/l, platelet counts less than 100 X 10(9)/l) at the start of therapy was associated with poor treatment results: none of six patients achieved a complete remission [41]. Eleven of 16 patients with no and 11 of 23 patients with one risk factor achieved a complete remission, as did only one patient with more than one risk factor. Survival rates after 30 months were: 87% with no, 66% with one, 36% with two, and 13% with more than two risk factors. We can conclude from our results that the prognosis of patients undergoing chemotherapy for Hodgkin's disease depends on the number of risk factors.
Similar articles
-
An unusual case of spontaneous remission of Hodgkin's disease after a single cycle of COPP-ABV chemotherapy followed by infectious complications.Yonsei Med J. 2005 Jun 30;46(3):425-30. doi: 10.3349/ymj.2005.46.3.425. Yonsei Med J. 2005. PMID: 15988816 Free PMC article. Review.
-
Lomustine, etoposide, vindesine, and dexamethasone (CEVD) in Hodgkin's lymphoma refractory to cyclophosphamide, vincristine, procarbazine, and prednisone (COPP) and doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD): a multicenter trial of the German Hodgkin Study Group.Cancer Treat Rep. 1987 Dec;71(12):1203-7. Cancer Treat Rep. 1987. PMID: 2446751
-
Combined cyclophosphamide vincristine, procarbazine, and prednisone (COPP) therapy of malignant lymphoma. Evaluation of 190 patients.Cancer. 1975 Oct;36(4):1241-9. doi: 10.1002/1097-0142(197510)36:4<1241::aid-cncr2820360409>3.0.co;2-5. Cancer. 1975. PMID: 1100220
-
Rapidly alternating COPP/ABV/IMEP is not superior to conventional alternating COPP/ABVD in combination with extended-field radiotherapy in intermediate-stage Hodgkin's lymphoma: final results of the German Hodgkin's Lymphoma Study Group Trial HD5.J Clin Oncol. 2002 Jan 15;20(2):476-84. doi: 10.1200/JCO.2002.20.2.476. J Clin Oncol. 2002. PMID: 11786577 Clinical Trial.
-
Relapse of Hodgkin's disease after 10 years of complete remission: case report.East Afr Med J. 1998 Mar;75(3):192-4. East Afr Med J. 1998. PMID: 9640822 Review.
References
MeSH terms
Substances
LinkOut - more resources
Medical